

July 7, 2016



bioAffinity Technologies Appoints New Senior VP for Research & Development of Therapeutics

SAN ANTONIO, July 07, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization of targeted drugs for the treatment of multiple cancers at bioAffinity's wholly owned subsidiary, OncoSelect Therapeutics, LLC.

"Dr. Bauta's 25 years of experience in the discovery, development and commercialization of pharmaceuticals for oncology and a wide array of life-threatening diseases will shorten the timeframe to adapt our proprietary porphyrin-based technology to the targeted cancer therapeutics market," said bioAffinity President and CEO Maria Zannes. "His expertise in the field of medicinal chemistry complements and builds upon the extraordinary caliber of our scientific team under the direction of Dr. Vivienne Rebel."

Dr. Bauta is currently the manager for medicinal and process chemistry at Southwest Research Institute where he helped develop its pharmaceuticals services and bioengineering business. Previously, he was Associate Director of science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in more than a dozen scientific journals, including the journal *Science*. Dr. Bauta received his Ph.D. from the University of Chicago where he received fellowships from the National Science Foundation and the American Chemical Society. His post-doctoral studies were at the University of Texas at Austin under a National Institutes of Health fellowship.

bioAffinity's porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence detectable by an imaging system. OncoSelect will take advantage of CyPath®'s unique characteristics to deliver targeted porphyrin therapeutics that will be available to partners through a variety of licensing agreements.

About bioAffinity Technologies

bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies' laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company's platform technology

will be developed to diagnose, monitor, and treat many cancers. CyPath[®] Lung, bioAffinity's initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.

Contact: Maria Zannes, 505.400.9747



Source: bioAffinity Technologies, Inc.